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Abstract The association between hypercholesterolemia
and elevated serum apolipoprotein B (APOB) has generated
interest in APOB as a therapeutic target for patients at risk
of developing cardiovascular disease. In the clinic, mi-
pomersen, an antisense oligonucleotide (ASO) APOB
inhibitor, was associated with a trend toward increased
hepatic triglycerides, and liver steatosis remains a concern.
We found that siRNA-mediated knockdown of ApoB led to
elevated hepatic triglycerides and liver steatosis in mice
engineered to exhibit a human-like lipid proﬁle. Many
genes required for fatty acid synthesis were reduced, sug-
gesting that the observed elevation in hepatic triglycerides
is maintained by the cell through fatty acid uptake as
opposed to fatty acid synthesis. Fatty acid transport protein
5( Fatp5/Slc27a5) is required for long chain fatty acid
(LCFA) uptake and bile acid reconjugation by the liver.
Fatp5 knockout mice exhibited lower levels of hepatic tri-
glycerides due to decreased fatty acid uptake, and shRNA-
mediated knockdown of Fatp5 protected mice from
diet-induced liver steatosis. Here, we evaluated if siRNA-
mediated knockdown of Fatp5 was sufﬁcient to alleviate
ApoB knockdown-induced steatosis. We determined that,
although Fatp5 siRNA treatment was sufﬁcient to increase
the proportion of unconjugated bile acids 100-fold, con-
sistent with FATP5’s role in bile acid reconjugation, Fatp5
knockdown failed to inﬂuence the degree, zonal distribu-
tion, or composition of the hepatic triglycerides that accu-
mulated following ApoB siRNA treatment.
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Introduction
Elevated LDL cholesterol (LDL-c) promotes atheroscle-
rosis, and it is well established that reducing LDL-c helps
to mitigate the risk of developing cardiovascular disease in
patients with hypercholesterolemia [1–7]. LDL-c consists
of a single apolipoprotein B-100 (APOB-100) molecule,
cholesterol, cholesterol-esters and triacylglycerols that are
comprised of various dietary and de novo synthesized fatty
acids [8]. In the liver, APOB is required for very low
density lipoprotein (VLDL) formation and serves as the
scaffold to solubilize cholesterol and fatty acids (in the
form of triglycerides) for secretion into the blood for cir-
culation [8]. An association between hypercholesterolemia
and increased APOB protein levels, together with the
observation that reductions in ApoB synthesis reduce LDL-
c and the incidence of atherosclerosis, has generated
interest in APOB as a therapeutic target [9–13]. Both
antisense oligonucleotides (ASOs) and small interfering
RNAs (siRNAs) targeting ApoB reduce LDL-c in mice and
in non-human primates [14–18]. In mice, ApoB ASOs
reduced LDL-c without inducing hepatic steatosis, a lia-
bility of microsomal transfer protein (MTP) inhibitors that
block triglyceride-rich lipoprotein assembly and secretion
[19]. In patients, mipomersen, an ApoB targeting ASO,
reduces both LDL-c and APOB, demonstrating the poten-
tial for an ApoB-targeted therapeutic [20–24]. Liver stea-
tosis induced by inhibiting ApoB, however, remains an
important concern. Recently, mipomersen administration at
a sub-maximum efﬁcacious dose was shown to be associ-
ated with a trend toward increased intra-hepatic triglycer-
ide (IHTG) content for mipomersen-treated patients with
one of the ten patients developing mild steatosis [20]. In
addition, mice harboring a base-pair deletion in the coding
region of ApoB (ApoB-38.9) exhibited hepatic triglyceride
accumulation [25]. In order to attenuate the risk of liver
steatosis associated with an ApoB-targeted therapeutic, one
approach would be to combine an ApoB ASO or siRNA
with another therapeutic that increases the clearance of
hepatic triglycerides.
Fatty acid transport protein 5 (Fatp5/Slc27a5) mediates
the uptake of long chain fatty acids (LCFAs) to the liver
and is involved in bile acid reconjugation during enter-
ohepatic recirculation [26, 27]. Fatp5 knockout mice
exhibit lower levels of hepatic triglycerides and free fatty
acids due to decreased liver fatty acid uptake [27]. Fur-
thermore, Doege et al. [25] recently showed that adeno-
virus-shRNA-mediated silencing of Fatp5 mRNA not
only protected mice from high fat diet-induced liver ste-
atosis but also reversed steatosis once it was established.
This suggested that a FATP5 inhibitor may be an
attractive combination therapy with an APOB-targeted
therapeutic.
Besides of its role in free fatty acid uptake, FATP5
also plays a critical role in reconjugation of bile acids
during enterohepatic recirculation to the liver, and com-
plete deletion of Fatp5 resulted in a signiﬁcant increase
in unconjugated bile acids in both bile and serum [26].
Activation of FXR, a bile acid nuclear receptor, with bile
acids or synthetic activators has been shown to reduce
the secretion of triglyceride-rich VLDL from the liver in
mice, which was associated with a decrease in Srebp1
and 2 pathway genes [28]. The involvement of FATP5 in
bile acid metabolism suggests that it too may play a role
in hepatic triglyceride metabolism via FXR. However,
the contributions of the bile acid reconjugation activity
of FATP5 on hepatic steatosis or the contribution of
FATP5 on APOB-induced steatosis are currently
unknown. By utilizing two siRNAs speciﬁcally targeting
Fatp5 and ApoB, we evaluated the ability of Fatp5
siRNA treatment to alleviate ApoB siRNA-induced liver
steatosis.
Materials and Methods
siRNA Design
siRNAs were designed to the mRNA transcripts using a
previously published design algorithm [34]. siRNA
sequences contained the following chemical modiﬁcations
added to the 20 position of the ribose sugar when indicated:
deoxy (d), 20 ﬂuoro (f), or 20 O-methyl (o) [34]. Modiﬁca-
tion abbreviations are givenimmediately preceding the base
to which they were applied. Passenger strands were capped
with an inverted abasic nucleotide on the 50 and 30 ends. The
control siRNA sequence (Cntrl siRNA) consists of:
iB;ﬂuU;ﬂuC;ﬂuU;ﬂuU;ﬂuU;ﬂuU;dA;dA;ﬂuC;ﬂuU;ﬂuC;
ﬂuU;ﬂuC;ﬂuU;ﬂuU;ﬂuC;dA;dG;dG;dT;dT;iB
passenger strand and
ﬂuC;ﬂuC;ﬂuU;omeG;omeA;omeA;omeG;omeA;omeG;
omeA;omeG;ﬂuU;ﬂuU;omeA;omeA;omeA;rA;rG;rA;omeU;
omeU guide strand sequences.
The Fatp5(951) siRNA sequence consists of:
iB;ﬂuC;ﬂuU;dG;ﬂuC;ﬂuC;dA;ﬂuU;dA;ﬂuU;ﬂuU;ﬂuC;dA;
ﬂuU;ﬂuC;ﬂuU;ﬂuU;ﬂuU;dA;ﬂuC;dT;dT;iB
passenger strand and
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omeA;ﬂuU;omeA;ﬂuU;omeG;omeG;ﬂuC;omeA;omeG;
omeU;omeU guide strand sequences.
The ApoB(10168) siRNA sequence consists of:
iB;ﬂuU;ﬂuC;dA;ﬂuU;ﬂuC;dA;ﬂuC;dA;ﬂuC;ﬂuU;dG;dA;
dA;ﬂuU;dA;ﬂuC;ﬂuC;dA;dA;dT;dT;iB
passenger strand and
rU;rU;rG;omeG;ﬂuU;omeA;ﬂuU;ﬂuU;ﬂuC;omeA;omeG;
ﬂuU;omeG;ﬂuU;omeG;omeA;ﬂuU;omeG;omeA;omeU;
omeU guide strand sequences.
siRNA Synthesis
siRNAs were synthesized by methods previously described
[35]. For each siRNA, the two individual strands were
synthesized separately using solid phase synthesis, and
puriﬁed by ion-exchange chromatography. The comple-
mentary strands were annealed to form the duplex siRNA.
The duplex was then ultraﬁltered and lyophilized to form
the dry siRNA. Duplex purity was monitored by LC/MS
and tested for the presence of endotoxin by standard
methods.
Preparation of siRNA-Lipid Nanoparticle (LNP)
Complex
LNPs were made as described previously [36]. The
encapsulation efﬁciency of the particles was determined
using a SYBR Gold ﬂuorescence assay in the absence and
presence of triton, and the particle size measurements were
performed using a Wyatt DynaPro plate reader. The siRNA
and lipid concentrations in the LNP were quantiﬁed by a
HPLC method, developed in house, using a PDA detector.
In Vivo siRNAs Treatments
All in vivo work was performed according to an approved
animal protocol as set by the Institutional American
Association for the Accreditation of Laboratory Animal
Care. C57Bl/6 mice engineered to be hemizygous for a
knockout of the LDL receptor and hemizygous for the
overexpression of the human cholesterol ester transfer
protein (CETP) driven by the endogenous apoA1 promoter
within a C57Bl/6 background [B6-Ldlr\tm1[Tg(apoA1-
CETP); Taconic] were used for these studies. Mice
*16–20 weeks of age were fed Lab Diets (5020 9F)
starting 2 weeks prior to the start of the study. siRNAs were
administered by intravenous (i.v.) injection. Animals were
dosed on days 0 and 14 with either 3 mg/kg of a single
LNP formulated siRNA or 1.5 mg/kg of two LNP formu-
lated siRNAs for a 3 mg/kg total siRNA combination dose.
For siRNA combinations, siRNA were formulated indi-
vidually and hand-mixed immediately prior to injections.
Animals were euthanized by CO2 inhalation. Immediately
after euthanasia, serum was collected using serum separa-
tor tubes and allowed to clot at room temperature for
30 min. Liver sections were excised, placed in either RNA
Later (Qiagen) (right medial lobe), 10% buffered formalin
(10% NBF, left medial lobe), or ﬂash frozen (the remain-
der), and stored until further use.
RNA Isolation and qRT-PCR
RNA was isolated using an RNeasy96 Universal Tissue Kit
(Qiagen) according to the supplied product protocol and as
described previously [37]. TaqMan Gene Expression
Assays (Applied Biosystems) were performed as described
within the product protocol using the following primer
probes, Mm00447768_m1 for Fatp5, Mm01545154_g1 for
ApoB, and Cat# 4352339E for the reference, Gapdh. All
reactions were performed in duplicate, and data were
analyzed using the ddCt method with Gapdh serving as in
[38]. Data represented as the log2-fold change (ddCt) rel-
ative to the control siRNA. For analysis of the selected
Srebp1c and Srebp2 pathway genes and Scd1, expression
was normalized to an average of that of mouse b-actin
(Actb), Glyceraldehyde 3-phosphate dehydrogenase (Gap-
dh), Beta-glucuronidase (Gusb), Hypoxanthine–guanine
phosphoribosyltransferase (Hprt1), Peptidylprolyl isomer-
ase A (Cyclophilin A/Ppia) and ribosomal protein 113a
(Rp113a) in each sample. Expression levels of all genes
analyzed were normalized to an average of the house-
keeping genes (listed above) to obtain dCt. Fold regulation
is calculated as: ddCt of gene in treatment group/dCt of
gene in control group. Signiﬁcance (p value) was calcu-
lated from a two-tailed t test between control and treatment
groups. Accession numbers for the primer/probes used are
listed in Supplemental Table 1.
Cholesterol and Triglyceride Analysis
Serum for cholesterol and triglyceride analysis was ana-
lyzed using Wako’s total and HDL cholesterol kits
according to the supplied product protocol and as described
previously [37]. Non-HDL, which serves as an approxi-
mation for LDL, was calculated by subtracting HDL from
total cholesterol measurements. The percent difference
relative to the control siRNA was calculated using the
following equation {100 9 [1-(experimental/control)]}.
Histology and Hematology
Mouse livers were ﬁxed with 10% neutral buffered for-
malin. One hepatic lobe was treated with osmium tetroxide
solution, to visualize lipids, overnight at room temperature
prior to parafﬁn embedding and processing. The other
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hematoxylin and eosin (H&E) stained. Samples were sec-
tioned at a thickness of 5 lm. The osmium-stained samples
were digitalized using an Aperio ScanScope XT. Percent
area (positive pixel count) was calculated using the positive
pixel count algorithm (MAN-0024) supplied with the
imaging software (Aperio). Samples were also reviewed by
a board-certiﬁed veterinary pathologist and scored for
inﬂammation and lipidosis using a semi-quantitative score.
Measurement of Serum APOB
The APOB levels in serum were measured by LC/MS as
described previously [29]. The concentration of APOB
peptide was calculated by dividing the area under the curve
for the analyte by the area of its internal standard and
multiplying by the internal standard concentration. The
concentration of APOB was then converted to and reported
as mg/dL.
LC/MS Sample Preparation and Analysis for Bile Acid
Conjugation and Hepatic Triglycerides
Terminal bile samples from each group were collected
using the stick and pull method. Samples were diluted
1:1,000 v/v in 50% acetonitrile ? 0.1% formic acid/50%
water ? 0.1% formic acid, followed by the addition of
1 lM total internal standard solution (D4-TCA, D4-CA,
D4-GCA) (Sigma-Isotec, St. Louis, MO, USA). The mix-
ture was vortexed for 10 s, centrifuged for 10 min at
15,000g, and then stored at -20 C until LC/MS analysis.
Supernatant was injected (10 lL) directly onto the LC/MS
system.
A 50-mg slice of frozen liver from each animal was
homogenized in 2-mL polypropylene tubes containing a
14-mm ceramic bead using a Precellys 24 homogenizer
(Bertin Technologies, Montigny-le-Bretonneux, France). A
non-naturally occurring internal standard solution (20 lL)
containing TG 51:0 (Sigma Aldrich, St Louis, MO, USA)
0.8 mg/mL along with dichloromethane/methanol (2:1 v/v)
was added to each sample prior to homogenization [39].
Samples were homogenized at 5,500 RPM, 2 9 30 s, with
a 15 s pause between cycles. In order to generate a two
layer liquid separation, 200 lL of distilled water was
added, vortexed for 30 s, followed by centrifugation at
20,000g at 5 C for 10 min. 10 lL of the lower layer,
containing the lipids, was removed without disrupting the
liver tissue homogenate disk. This was followed by dilution
of the extracted lipid sample 1/50 in a solvent mixture
(65% ACN, 30% IPA, 5% H2O).
External endogenous calibration standards in buffer
solution were used to cover the endogenous
concentrations present in the bile and liver tissues. The
inlet system was comprised of an Acquity UPLC (Waters,
Milford, MA, USA). Bile and lipid extracts were injected
(2 lL) onto a 1.8-lm particle 100 9 2.1 mm id Waters
Acquity HSS T3 column (Waters). The column was
maintained at 55 C with a 0.4-mL/min ﬂow rate for the
lipid analysis and 65 C with a 0.7-mL/min ﬂow rate for
the bile analysis. A binary gradient system was utilized
for the analysis of both sample sets. Two different gra-
dient conditions were used. For the lipid analysis, the
same conditions were used as previously described [40].
For the bile acid analysis, water ? 0.1% formic acid was
used as eluent A. Eluent B consisted of acetoni-
trile ? 0.1% formic acid (Burdick & Jackson, USA). A
linear gradient (curve 6) was performed over a 13-min
total run time. During the initial portion of the gradient, it
was held at 80% A and 20% B. For the next 10 min, the
gradient was ramped in a stepped linear fashion to 35% B
(curve 5) in 4 min, 45% B in 7.5 min and 99% B in
9.5 min and held at this composition for 1.6 min. Here-
after, the system was switched back to 80% B and 20% A
and equilibrated for an additional 2.9 min.
The inlet system described was directly coupled to a
hybrid quadrupole orthogonal time of ﬂight mass spec-
trometer (SYNAPT G2 HDMS; Waters MS Technologies,
Manchester, UK). Electrospray (ESI) positive and nega-
tive ion ionization modes were used. In both ESI modes,
a capillary voltage and cone voltage of ±2k V
and ±30 V, respectively, were used. The desolvation
source conditions were as follows: for the desolvation gas
700 L/h was used and the desolvation temperature was
kept at 450 C. Data were acquired over the mass range
of 50–1,200 Da.
The LC/MS data acquired was processed by the use of a
quantitative data deconvolution package (Positive software
by MassLynx; Waters, MA, USA). Data are presented
as ± standard error of the mean (SEM). Differences
between groups were computed by either Student’s t test or
by two-way ANOVA (GraphPad Prism, La Jolla, CA,
USA). Post-test analysis for quantiﬁable variables was
conducted using either Bonferroni or Mann–Whitney
U non-parametric test with two-tailed p values. Values of
p\0.05 were considered statistically signiﬁcant.
Lipid Nomenclature
The nomenclature utilized in this manuscript is in accor-
dance with Lipidmaps (http://www.lipidmaps.org). In brief,
a triglyceride described as TG 52:2 is interpreted as a tri-
glyceride containing 52 carbons attached to the glycerol
back-bone and two double bonds in the fatty acyl chain as
described by Fahy et al. [41].
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Sustained Knockdown of Both ApoB and Fatp5 mRNA
Transcripts was Achieved with siRNAs Administered
Either Alone or in Combination
To investigate if we can simultaneously silence both ApoB
and Fatp5, we administered siRNAs speciﬁcally targeting
ApoB and Fatp5, alone and in combination, to CETP/
LDLR hemizygous female mice (mice exhibiting a human-
like lipid proﬁle) fed a low-fat western diet. Changes to the
lipid proﬁle were obtained through a hemizygous mutation
of the LDL receptor (±LDLR) and the hemizygous over-
expression of a mouse apoA1 promoter-driven human
CETP transgene (±apoA1-hCETP). This led to an eleva-
tion in LDL and a cholesterol proﬁle that more closely
resembled the HDL–LDL ratio observed in humans [29].
Female mice were fed a low-fat western diet ad libitum and
treated with siRNAs formulated in a lipid nanoparticle
(LNP) to achieve delivery to the liver [30]. Animals were
dosed on days 0 and 14 with either 3 mg/kg of a single
siRNA or 1.5 mg/kg of two siRNAs for a 3 mg/kg total
siRNA combination dose. Efﬁcacy was analyzed using
qRT-PCR on liver samples collected on day 21. Analysis of
mRNA expression levels revealed no appreciable differ-
ence in knockdown (KD) between ApoB siRNA treatments
administered either alone or in combination with the Fatp5
siRNA (Fig. 1a; C90% KD across all groups). Similar
results were observed for the Fatp5 siRNA, where C89%
knockdown of Fatp5 was observed (Fig. 1b).
Fatp5 Knockdown Impaired Bile Acid Reconjugation
The ratio of unconjugated/conjugated bile acid in the bile
was used as a biological indicator for the loss of FATP5
activity following siRNA treatment to female mice fed a
low-fat western diet ad libitum [26]. A signiﬁcant
increase in the proportion of unconjugated bile acids was
observed for all Fatp5 siRNA treatment groups, indicative
of the loss of FATP5 activity (Fig. 2a; p = 0.0003, t test,
Mann–Whitney post-test, cntrl siRNA groups vs. Fatp5
siRNA groups). The unconjugated/conjugated ratio for the
cntrl/cntrl siRNA group and the Fatp5/Fatp5 siRNA
group was 0.004 and 2.2, respectively. The ratio was
lower for some of the Fatp5 siRNA treatment groups
when combined with the ApoB siRNA, but nevertheless
exhibited a signiﬁcant level of target engagement when
compared with the control siRNA. Cholic acid in the
Fatp5 groups was the most predominant unconjugated
bile acid found in bile (Fig. 2b), which showed a dramatic
increase in concentration (0.77 mM in control siRNA vs.
77.95 mM in Fatp5) after knockdown of Fatp5
(p = 0.0003, t test, Mann–Whitney post-test). Conjugated
bile acids, speciﬁcally taurocholic acid (TCA), showed
the reverse effect following Fatp5 knockdown
(p = 0.1304, t test, Mann–Whitney post-test). The levels
of TCA decreased to 43.2 mM in comparison with the
cntrl siRNA group 69.7 mM (data not shown). The ratio
of unconjugated/conjugated bile acid in the serum
reﬂected that of the bile, with a signiﬁcant increase in the
unconjugated levels (data not shown).
Fig. 1 Similar levels of ApoB and Fatp5 mRNAs were observed for
all groups containing siRNAs targeting these genes, either alone or in
combination. Mice (n = 8/group) were treated with siRNAs targeting
ApoB and Fatp5 alone or in combination (ApoB, Fatp5, Fatp5/ApoB)
at days 0 and 14. Gene expression was analyzed using qRT-PCR
(TaqMan) on day 21 (a, b) post the initial dose. PBS and a control
siRNA (cntrl siRNA) served as negative controls. Data represented as
the log2 fold change (ddCt) relative to the cntrl siRNA treatment of
individual animals (circles) and the group means (bars) are shown
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in Serum APOB Protein, Cholesterol and Triglyceride
Levels Alone and in Combination
with a Fatp5-Targeting siRNA
ApoB siRNA treatment, either alone or in combination with
a siRNA targeting Fatp5, caused a signiﬁcant reduction
(p B 0.001) in serum APOB levels in female mice fed a
low-fat western diet ad libitum (Fig. 3). APOB protein
reductions were consistent with the reductions in hepatic
ApoB mRNA levels (Fig 1a). This led to reductions in
circulating cholesterol and triglyceride levels. On day 21,
similar reductions in total (76–84%), HDL (67–78%), and
non-HDL (79–90%) cholesterol were observed across all
ApoB siRNA treatment groups (Fig. 4a–c). No signiﬁcant
decrease in cholesterol levels were observed for the
ApoB ? Fatp5 siRNA combination group relative to the
ApoB siRNA individual treatment group.
Serum triglycerides were also signiﬁcantly reduced for
ApoB siRNA treatments either alone or in combination on
day 21 (Fig. 4d). Taken together, these data point to similar
and signiﬁcant changes in serum cholesterol across ApoB
siRNA treatment groups that correlated with the observed
reductions in ApoB mRNA and serum protein levels.
Fatp5 siRNA Treatment Failed to Alleviate ApoB
siRNA-induced Liver Steatosis
To determine if Fatp5 siRNA treatment was sufﬁcient to
alleviate ApoB siRNA-induced liver steatosis, liver sec-
tions were processed, sectioned, and stained with either
osmium or H&E. Image analysis of the osmium stained
slides revealed similar levels of signiﬁcant lipid accumu-
lation across all ApoB siRNA treatment groups relative to
the PBS, Fatp5, or control siRNA groups (Fig. 5a, b).
These data indicated that Fatp5 siRNA treatment failed to
alleviate ApoB siRNA-induced liver steatosis in female
mice fed a low-fat western diet ad libitum. For the PBS,
Fatp5, and control siRNA groups, there was some evidence
of a periportal to midzonal (zones 1 and 2) distribution of
lipid droplets within hepatocytes (Fig. 5b). This contrasted
the lipid distribution following ApoB siRNA treatment,
Fig. 2 Fatp5 knockdown reduces bile acid (BA) reconjugation. a An
increase in the level of unconjugated/conjugated bile acid ratio
(***p B 0.001, t test, Mann–Whitney post-test) was observed
following Fatp5 knockdown. b Cholic acid (CA) concentrations
exhibited an increase in the concentration measured (***p B 0.001,t
test, Mann–Whitney post-test) by LC/MS after treatment with the
Fatp5 siRNA. Data represented as the group means (bars) ± SD
(n = 8/group)
Fig. 3 Serum APOB protein levels were reduced following ApoB
siRNA treatment. APOB levels in serum were measured by LC/MS
on day 21 following days 0 and 14 doses as indicated on the x-axis.
Data represented as the group means (bars) ± SD (n = 8/group).
Signiﬁcance (***p B 0.0001) relative to the siRNA control-treated
group was calculated using a one-way ANOVA, Tukey post-test
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(Fig. 5b). The ApoB-treated groups displayed lipid droplets
that were smaller and more evenly distributed, while fewer
but larger lipid droplets were observed for the remaining
groups in many instances and as shown in Fig. 5b. By H&E
staining, hepatocytes in the ApoB siRNA treatment groups
appeared diffusely swollen, with granular to vacuolated
cytoplasmic spaces (data not shown).
Fatp5 Knockdown Failed to Alter ApoB siRNA-
induced Liver Triglyceride levels or Composition
Total triglyceride composition analysis by LC/MS revealed
a signiﬁcant increase in the level of triglycerides found in
the liver following treatment with ApoB siRNA when
compared with siRNA control (Fig. 6a; Cntrl siRNA
7.5 lg/mg of tissue vs. ApoB siRNA 35.5 lg/mg of tissue,
p = 0.0002,ttest with Mann–Whitney post-test). Com-
parative measurements between the ApoB/ApoB and the
Fatp5/Fatp5 ? ApoB groups demonstrated that there was
no protection from triglyceride accumulation in female
mice fed a low-fat western diet ad libitum. LC/MS indi-
cated that triglycerides 52:2 and 52:3 were signiﬁcantly
higher (p B 0.0001, two-way ANOVA with Bonferroni
post-test) following Fatp5/Fatp5 ? ApoB treatment rela-
tive to ApoB/ApoB treatment (Fig. 6b). Triglycerides 52:4
and 54:3, although not statistically signiﬁcant, also showed
an increase in the Fatp5/Fatp5 ? ApoB cohort in
Fig. 4 Comparable levels of serum cholesterol and triglycerides were
observed for ApoB siRNA treatments either alone or in combination
with a siRNA-targeting Fatp5. Total cholesterol (a), HDL cholesterol
(b), and triglycerides (d) were measured on day 21 following days 0
and 14 doses as indicated on the x-axis. Non-HDL cholesterol (c) was
calculated by subtracting the HDL cholesterol value from the total
cholesterol value. Data represented as group means (bars) ± SD
(n = 8/group). The percent difference relative to the control siRNA is
shown. Signiﬁcance (***p B 0.0001) was calculated using a one-way
ANOVA, Tukey post-test, and reported for treated groups relative to
the siRNA control (cntrl siRNA) treatment
Lipids (2011) 46:991–1003 997
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dation by collision-induced dissociation MS/MS provided
information about the possible fatty acid composition for
each triglyceride. Triglyceride 52:2 contained 16:0/18:1/
18:1, triglyceride 52:3 contained 16:0/18:1/18:2, triglyc-
eride 54:3 contained 18:1/18:1/18:1 and triglyceride 54:3
contained 18:1/18:2/18:1. These triglycerides were con-
ﬁrmed by accurate mass and the use of external standards
(data not shown). All of these signiﬁcantly relevant tri-
glycerides have constituent fatty acids which are non-
essential, suggesting that they may be derived from de
novo synthesis.
The Hepatic Sterol Response Differed After ApoB
and Fatp5 siRNA Treatments
To investigate the hepatic gene response to ApoB, Fatp5 or
combination treatments, we performed qRT-PCR analysis
on genes involved in the sterol response element binding
protein 1 and 2 pathways (Srebp1 and Srebp2). Interest-
ingly, although ApoB knockdown induced steatosis, it
resulted in a signiﬁcant decrease in many genes involved in
both pathways (Table 1), including genes that are key
regulators of fatty acid and triglyceride synthesis (Fasn,
Scd, Fads1/2, Acsl3/5). As previously described, deletion
Fig. 5 Similar levels of liver steatosis were observed across all ApoB
siRNA treatment groups. a Osmium-stained images were digitized
and pixel intensities were quantitated for day 21. Data represented as
the group mean ± SD (n = 8/group). b Images representative of each
of the treatment groups are shown
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123[31] or silencing [25]o fFatp5 caused a reduced uptake of
hepatic free fatty acids from serum, which caused a sub-
sequent increase in genes involved in fatty acid synthesis.
In contrast to ApoB siRNA treatment, Table 1 shows that
Fatp5 siRNA treatment resulted in a signiﬁcant increase in
both Srebp1 and Srebp2 pathways. Although bile acid
conjugation levels changed and there was a signiﬁcant
increase in cholic acid in bile (Fig 3b), transcription of
FXR or key regulators of FXR did not change (data not
shown). ApoB siRNA treatment appeared to have a stron-
ger effect on the Srebp1/2 pathways than Fatp5 siRNA
since the simultaneous reductions of both resulted in a
hepatic gene signature more similar to that of ApoB siRNA
treatment alone.
Discussion
In this report, we found that siRNA-mediated knockdown
of ApoB led to a signiﬁcant reduction in serum lipids,
including HDL, which was associated with an increase in
hepatic triglycerides leading to liver steatosis in CETP/
LDLR hemizygous mice (a mouse model having a human-
like lipid proﬁle). It is worth noting that similar results
were observed on day 28 for all end points measured
[mRNA knockdown, serum lipids, and histological analysis
of hepatic lipid levels (data not shown)].
ApoB siRNA-mediated steatosis contrasts with results
reported for ASO-mediated ApoB knockdown where only
modest but not signiﬁcant increases in hepatic triglycerides
were observed following 6 weeks of biweekly (25 mg/kg)
treatment that resolved by week 20 [14]. Crooke et al.
reasoned that a compensatory mechanism, which included
the activation of AMPK leading to increased fatty acid
oxidation and the down-regulation of genes involved in
fatty acid synthesis and transport, led to the resolution of
hepatic triglyceride accumulation [14]. However, we also
observed decreased gene expression within these pathways
following the knockdown of ApoB. In addition, we
observed increased serum ketone levels following ApoB
siRNA treatment, which is indicative of increased fatty
acid oxidation (data not shown). Furthermore, mice har-
boring a base-pair deletion in the coding region of ApoB
(ApoB-38.9) also exhibited hepatic triglyceride accumula-
tion and decreased expression of genes involved in fatty
acid synthesis [25]. Taken together, these data suggest that
an alternative mechanism may explain the lack of ASO-
mediated steatosis and the discrepancy between ApoB
Fig. 6 Fatp5 siRNA treatment
fails to alter ApoB siRNA-
induced liver triglyceride levels
or composition. The total
triglyceride pool size and
composition was measured for
different siRNA administrations
(Cntrl siRNA/Cntrl siRNA,
ApoB/ApoB, Fatp5/Fatp5 and
Fatp5/Fatp5 ? ApoB). a A
large increase in liver
triglycerides was observed for
the ApoB/ApoB group relative to
the control siRNA
(***p = 0.0002,ttest with
Mann–Whitney post-test).
Fatp5 siRNA treatment (Fatp5/
Fatp5 ? ApoB) did not show
protection from ApoB siRNA-
induced liver steatosis.
b Speciﬁc triglycerides TG 52:2
and TG 52:3 showed an increase
in their concentrations in both
the ApoB/ApoB and Fatp5/
Fatp5 ? ApoB groups
suggesting that Fatp5
knockdown fails to alter the
triglyceride composition
induced by ApoB knockdown
(***p B 0.0001, two-way
ANOVA with Bonferroni post-
test)
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123siRNA and ASO treatments, which could be explained, at
least in part, by the fact that we are observing slightly
greater ApoB knockdown (*90 vs. *75%) and cholesterol
lowering [*80 (non-HDL) vs. 66% (LDL)] relative to the
ASO-mediated changes.
From our results, HDL appears lower and serum tri-
glycerides higher than one would initially expect for ApoB
knockdown. While the cause of the decrease in HDL fol-
lowing ApoB siRNA treatment is unknown, it is likely that
the HDL components provided by APOB-containing par-
ticles are reduced following ApoB knockdown leading to a
reduction HDL levels, which is consistent with ﬁndings by
Tadin-Strapps et al. [29, 31]. In addition, while serum tri-
glycerides appear disproportionately higher relative to
serum APOB for ApoB siRNA-treated groups (Fig. 3 rel-
ative to Fig. 4d), some of this apparent discrepancy could
be due to the production of larger, more triglyceride-rich,
non-HDL particles for the limited number of particles
produced. It also remains likely that serum triglycerides are
artiﬁcially elevated relative to other endpoints, since serum
triglycerides are measured enzymatically and glycerol is a
reaction intermediate. Thus, any glycerol within the serum
would lead to a higher reading than would otherwise be
expected.
Fatty acids are either transported into the liver or syn-
thesized de novo. Since fatty acids are required for tri-
glyceride synthesis and ApoB knockdown reduced the
expression of many of the genes involved in de novo
hepatic fatty acid synthesis, we rationalized that liver ste-
atosis induced by ApoB knockdown could be maintained, at
least in part, by the accumulation of fatty acids taken up by
hepatocytes [29]. FATP5 is a transporter of long chain fatty
acids (LCFAs) into hepatocytes [27, 32], and we reasoned
that reducing LCFA uptake by knocking-down Fatp5
would reduce hepatic triglyceride levels induced by ApoB
knockdown. We found that Fatp5 knockdown does not
inﬂuence the size, composition, or zonal distribution of the
hepatic triglyceride pool generated by ApoB siRNA treat-
ment. Lipid levels for the Fatp5 siRNA treatment alone
were too low to reliably assess differences in the hepatic
triglyceride population relative to the control siRNA group,
although results reported by Doege et al. [27] would
Table 1 Srebp1c and Srebp2 gene expression changes observed following ApoB, Fatp5, and combination siRNA treatments
Gene ApoB Fatp5 Fatp5/Fatp5 ? ApoB
Fold regulation p value Fold regulation p value Fold regulation p value
Srebp1c pathway Acaca –1.46 0.0705 1.78
a 0.0156 –1.86
b 0.0266
Acacb –1.69
b 0.0084 1.61
a 0.0070 –5.40
b 0.0098
Fasn –2.99
b 0.0026 2.05
a 0.0203 –2.03 0.0830
Scd –3.62
b 0.0009 1.95
a 0.0007 –2.91
b 0.0104
Fads1 –2.18
b 0.0000 1.13 0.0514 –2.18
b 0.0000
Fads2 –2.39
b 0.0000 1.24 0.0705 –2.36
b 0.0001
Acsf2 1.36
a 0.0075 1.12 0.0792 1.28
a 0.0074
Acsl1 1.19 0.1635 –1.18 0.3571 1.06 0.6852
Acsl3 –2.16
b 0.0002 1.05 0.8005 –1.76
b 0.0202
Acsl4 –1.24 0.1148 –1.10 0.3702 –1.25 0.0948
Acsl5 –1.28
b 0.0405 1.40
a 0.0020 –1.40
b 0.0475
Srebp2 pathway Hmgcs1 –1.60
b 0.0238 1.93
a 0.0020 –1.24 0.3368
Hmgcr –2.23
b 0.0034 1.72 0.0740 –1.30 0.5900
Mvk –1.11 0.3513 1.51
a 0.0086 –1.02 0.8580
Pmvk –2.30
b 0.0004 1.52
a 0.0068 –2.33
b 0.0033
Mvd –3.26
b 0.0033 1.94
a 0.0072 –1.98 0.0528
Idi1 –1.63
b 0.0212 1.99
a 0.0017 –1.24 0.3330
Fdps –2.60
b 0.0022 1.88
a 0.0039 –2.20
b 0.0237
Fdft1 –1.43
b 0.0095 1.72
a 0.0011 –1.10 0.6770
Cyp51a1 –1.75
b 0.0058 1.81
a 0.0010 –1.40 0.1238
Dhcr7 –1.65
b 0.0065 1.65
a 0.0007 –1.54 0.1193
Selected Srebp1 and Srebp2 pathway genes were analyzed after siRNA treatments. Mice were treated with siRNAs targeting ApoB and Fatp5
alone or in combination (ApoB, Fatp5, Fatp5/ApoB) at days 0 and 14. Gene expression was analyzed using qRT-PCR (TaqMan) on day 21. Fold
regulation was calculated for the treatment group relative to the control siRNA group.
a Indicates a signiﬁcant induction (p B 0.05) and
ba signiﬁcant reduction (p B 0.05) in expression relative to the control siRNA group.
Signiﬁcance (p value) was calculated using a two-tailed t test between control and treatment groups
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123suggest that reductions in FATP5 would disproportionately
decrease the saturated and polyunsaturated fatty acid con-
taining triglycerides relative to monounsaturated fatty acid
containing triglycerides.
It remains possible that FATP5 may not function as a
transporter of fatty acids under our conditions. In the studies
reported here, animals were fed a chow diet containing 9%
fat ad libitum, whereas Fatp5 knockout mice fed a similar
diet (a chow diet containing 5% fat) exhibited the most
dramatic changes in hepatic lipid accumulation under pro-
longed fasting conditions [32]. One could also argue that
Fatp5 knockdown may induce the expression of other Fatp
family members, which could compensate for the loss of
FATP5 activity under our conditions. However, this is
unlikely, since Fatp5 knockout mice did not exhibit altered
expression of Fatp1-4 or Fatp6 [32], and we did not observe
a change in the expression of either of the two Fatps
evaluated (Fatp2 or Fatp4, data not shown). Alternatively,
both Fatp2 and Fatp5 are highly expressed in liver, and
Fatp2 knockdown has also been reported to decrease
hepatic fatty acid uptake in mice [33]. Therefore, it remains
possible that FATP2 is sufﬁcient to mediate hepatic fatty
acid uptake in the absence of FATP5 under our conditions.
Even though Fatp5 knockdown failed to inﬂuence the
hepatic triglyceride pool generated following ApoB
knockdown, it did lead to a 100-fold increase in ratio of
unconjugated to conjugated bile acids. The magnitude of
the shift within the bile acid pool, from predominately
conjugated to predominately unconjugated bile acids, is
consistent with FATP5 being required for the majority of
bile acid reconjugation during enterohepatic recirculation.
Our results are inline with the results reported for Fatp5
knockout mice and suggest that Fatp5 siRNA treatment is
sufﬁcient to inﬂuence FATP5 activity [26]. We expect
these changes to have only a minor effect on fat absorption,
since, consistent with Hubbard et al. [26], we observed that
unconjugated bile acids are found within gall bladder bile.
Thus, unconjugated bile acids can be efﬁciently secreted
into bile following Fatp5 knockdown and should therefore
be available for fat absorption. Fatp5 knockout mice also
exhibited secondary metabolic changes leading to
decreased food intake. Although, it is unclear if this is due
to altered bile acid metabolism via the inhibition of bile
acid reconjugation, altered lipid metabolism via the inhi-
bition of fatty acid uptake, or both. While outside the scope
of this work, it remains possible to use siRNAs targeting
Fatp5 to address this question, since we observed the
inhibition of bile acid reconjugation but not fatty acid
uptake under these conditions.
Finally, we have shown that Fatp5 knockdown resulted
in a signiﬁcant increase in genes involved in hepatic cho-
lesterol biosynthesis (Srebp2 pathway) and fatty acid syn-
thesis (Srebp1 pathway). This is consistent with the
increase in fatty acid synthase expression and defects in
bile acid reconjugation reported for the loss of FATP5
activity [26, 27].
One could, therefore, speculate that changes in bile acid
conjugation levels would result in an increase in de novo
cholesterol synthesis, requiring more acetyl-CoA, which
may promote fatty acid synthesis.
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